Cellectis
CLLS
$2.56
Share price
1.59%
Change (1 day)
31.28%
Change (1 year)
Categories
Cellectis (CLLS) - Total liabilities
Total liabilities on the balance sheet as of September 2023 : $0.13 B
According to Cellectis's latest financial reports the company's total liabilities are $0.13 B. A company’s total liabilities is the sum of all current and non-current debts and obligations.
Cellectis - Total liabilities on balance sheet (from 2008 to 2023)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2022-12-31 | $0.13 B | -7.09% |
| 2021-12-31 | $0.14 B | -9.35% |
| 2020-12-31 | $0.16 B | 43.42% |
| 2019-12-31 | $0.11 B | 121.48% |
| 2018-12-31 | $50.56 M | 3.42% |
| 2017-12-31 | $48.89 M | -13.85% |
| 2016-12-31 | $56.76 M | -32.96% |
| 2015-12-31 | $84.66 M | -10.83% |
| 2014-12-31 | $94.95 M | 160.89% |
| 2013-12-31 | $36.39 M | 14.58% |
| 2012-12-31 | $31.76 M | -66.51% |
| 2011-12-31 | $94.86 M | 400.24% |
| 2010-12-31 | $18.96 M | -11.42% |
| 2009-12-31 | $21.4 M | 47.96% |
| 2008-12-31 | $14.46 M | 40.07% |
| 2007-12-31 | $10.32 M |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Regeneron Pharmaceuticals REGN | $7.10 B | 5,220.60% | 🇺🇸 USA |
 uniQure QURE | $0.62 B | 367.16% | 🇳🇱 Netherlands |
 Novavax NVAX | $2.51 B | 1,782.37% | 🇺🇸 USA |